Chun Li

Chun Li

Auto-generated profile, based on publicly available information

Chun Li

Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, U.S.A.

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
USUte I. Schwarz
Ute I. Schwarz
MRMarylyn D. Ritchie
Marylyn D. Ritchie
YBYuki Bradford
Yuki Bradford
CLChun Li
Chun Li
SDScott M. Dudek
Scott M. Dudek
CSC. Michael Stein
C. Michael Stein
Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear. In 297 patients starting warfarin therapy, we assessed CYP2C9 genotypes (CYP2C9 *1, *2, and *3), VKORC1 haplotypes (designated A and non-A), clinical characteristics, response to therapy (as determined by the international normalized ratio [INR]), and bleeding events. The study outcomes were the time to the first INR within the therapeutic range, the time to the first INR of more than 4, the time above the therapeutic INR range, the INR response over time, and the warfarin dose requirement. As compared with patients with the non-A/non-A haplotype, patients with the A/A haplotype of VKORC1 had a decreased time to the first INR within the therapeutic range (P=0.02) and to the first INR of more than 4 (P=0.003). In contrast, the CYP2C9 genotype was not a significant predictor of the time to the first INR within the therapeutic range (P=0.57) but was a significant predictor of the time to the first INR of more than 4 (P=0.03). Both the CYP2C9 genotype and VKORC1 haplotype had a significant influence on the required warfarin dose after the first 2 weeks of therapy. Initial variability in the INR response to warfarin was more strongly associated with genetic variability in the pharmacologic target of warfarin, VKORC1, than with CYP2C9.

15 February 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
WZWei Zheng
Wei Zheng
JLJirong Long
Jirong Long
YGYu-Tang Gao
Yu-Tang Gao
CLChun Li
Chun Li
YZYing Zheng
Ying Zheng
XSXiao-Ou Shu
Xiao-Ou Shu
Wei Zheng and colleagues carried out a genome-wide association study of breast cancer in Chinese women and discovered risk variants on 6q25.1 located upstream of the gene encoding estrogen receptor 1 (ESR1). They also found a similar association between the 6q25.1 locus and breast cancer in samples of European ancestry. We carried out a genome-wide association study among Chinese women to identify risk variants for breast cancer. After analyzing 607,728 SNPs in 1,505 cases and 1,522 controls, we selected 29 SNPs for a fast-track replication in an independent set of 1,554 cases and 1,576 controls. We further investigated four replicated loci in a third set of samples comprising 3,472 cases and 900 controls. SNP rs2046210 at 6q25.1, located upstream of the gene encoding estrogen receptor α (ESR1), showed strong and consistent association with breast cancer across all three stages. Adjusted odds ratio (95% CI) were 1.36 (1.24–1.49) and 1.59 (1.40–1.82), respectively, for genotypes A/G and A/A versus G/G (P for trend 2.0 × 10−15) in the pooled analysis of samples from all three stages. We also found a similar, albeit weaker, association in an independent study comprising 1,591 cases and 1,466 controls of European ancestry (Ptrend = 0.01). These results strongly implicate 6q25.1 as a susceptibility locus for breast cancer.

19 February 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe Genetic Investigation of ANthropometric Traits (GIANT) Consortium
The Genetic Investigation of ANthropometric Traits (GIANT) Consortium
WWWanqing Wen
Wanqing Wen
YCYoon-Shin Cho
Yoon-Shin Cho
WZWei Zheng
Wei Zheng
RDRajkumar Dorajoo
Rajkumar Dorajoo
XSXiao-Ou Shu
Xiao-Ou Shu
Xiao-Ou Shu and colleagues report a meta-analysis of genome-wide association studies for body mass index (BMI) in east Asians. They identify three new genetic loci associated with BMI. Multiple genetic loci associated with obesity or body mass index (BMI) have been identified through genome-wide association studies conducted predominantly in populations of European ancestry. We performed a meta-analysis of associations between BMI and approximately 2.4 million SNPs in 27,715 east Asians, which was followed by in silico and de novo replication studies in 37,691 and 17,642 additional east Asians, respectively. We identified ten BMI-associated loci at genome-wide significance (P < 5.0 × 10−8), including seven previously identified loci (FTO, SEC16B, MC4R, GIPR-QPCTL, ADCY3-DNAJC27, BDNF and MAP2K5) and three novel loci in or near the CDKAL1, PCSK1 and GP2 genes. Three additional loci nearly reached the genome-wide significance threshold, including two previously identified loci in the GNPDA2 and TFAP2B genes and a newly identified signal near PAX6, all of which were associated with BMI with P < 5.0 × 10−7. Findings from this study may shed light on new pathways involved in obesity and demonstrate the value of conducting genetic studies in non-European populations.

1 August 2005 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JSJames S. Sutcliffe
James S. Sutcliffe
RDRyan J. Delahanty
Ryan J. Delahanty
HPHarish C. Prasad
Harish C. Prasad
JMJacob L. McCauley
Jacob L. McCauley
QHQiao Han
Qiao Han
RBRandy D. Blakely
Randy D. Blakely

18 May 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
BZBen Zhang
Ben Zhang
G(Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)
Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)
WJWei-Hua Jia
Wei-Hua Jia
KMKoichi Matsuda
Koichi Matsuda
SKSun-Seog Kweon
Sun-Seog Kweon
C(Colon Cancer Family Registry (Ccfr)
Colon Cancer Family Registry (Ccfr)
Wei Zheng and colleagues report the results of a large-scale genome-wide association study of colorectal cancer in East Asians. They identify six new susceptibility loci, including variants near TCF7L2 and TGFB1. Known genetic loci explain only a small proportion of the familial relative risk of colorectal cancer (CRC). We conducted a genome-wide association study of CRC in East Asians with 14,963 cases and 31,945 controls and identified 6 new loci associated with CRC risk (P = 3.42 × 10−8 to 9.22 × 10−21) at 10q22.3, 10q25.2, 11q12.2, 12p13.31, 17p13.3 and 19q13.2. Two of these loci map to genes (TCF7L2 and TGFB1) with established roles in colorectal tumorigenesis. Four other loci are located in or near genes involved in transcriptional regulation (ZMIZ1), genome maintenance (FEN1), fatty acid metabolism (FADS1 and FADS2), cancer cell motility and metastasis (CD9), and cell growth and differentiation (NXN). We also found suggestive evidence for three additional loci associated with CRC risk near genome-wide significance at 8q24.11, 10q21.1 and 10q24.2. Furthermore, we replicated 22 previously reported CRC-associated loci. Our study provides insights into the genetic basis of CRC and suggests the involvement of new biological pathways.

1 April 2004 in Diabetes
Verified
Journal Article
Open access
PDF file
KSKaisa Silander
Kaisa Silander
KMKaren L. Mohlke
Karen L. Mohlke
LSLaura J. Scott
Laura J. Scott
EPErin C. Peck
Erin C. Peck
PHPablo Hollstein
Pablo Hollstein
FCFrancis S. Collins
Francis S. Collins
The Finland-United States Investigation Of NIDDM Genetics (FUSION) study aims to identify genetic variants that predispose to type 2 diabetes by studying affected sibling pair families from Finland. Chromosome 20 showed our strongest initial evidence for linkage. It currently has a maximum logarithm of odds (LOD) score of 2.48 at 70 cM in a set of 495 families. In this study, we searched for diabetes susceptibility variant(s) at 20q13 by genotyping single nucleotide polymorphism (SNP) markers in case and control DNA pools. Of 291 SNPs successfully typed in a 7.5-Mb interval, the strongest association confirmed by individual genotyping was with SNP rs2144908, located 1.3 kb downstream of the primary β-cell promoter P2 of hepatocyte nuclear factor-4α (HNF4A). This SNP showed association with diabetes disease status (odds ratio [OR] 1.33, 95% CI 1.06–1.65, P = 0.011) and with several diabetes-related traits. Most of the evidence for linkage at 20q13 could be attributed to the families carrying the risk allele. We subsequently found nine additional associated SNPs spanning a 64-kb region, including the P2 and P1 promoters and exons 1–3. Our results and the independent observation of association of SNPs near the P2 promoter with diabetes in a separate study population of Ashkenazi Jewish origin suggests that variant(s) located near or within HNF4A increases susceptibility to type 2 diabetes.